Alessa Therapeutics

Founded in 2018 in San Carlos, US, Alessa Therapeutics specializes in localized drug delivery for prostate-related conditions.000 mn.Alessa Therapeutics specializes in developing innovative localized drug delivery systems primarily targeting prostate cancer and benign prostate hyperplasia. The company’s core product offerings focus on implantable drug delivery systems designed to administer anti-androgen therapies directly to tumors in a sustained manner, minimizing systemic exposure and enhancing therapeutic efficacy. These systems aim to address critical needs in oncology, particularly for early-stage cancers, by providing a more tolerable and effective treatment alternative. The company is currently conducting clinical studies to validate the effectiveness of these technologies, engaging healthcare providers and oncologists as key customers in the United States and Australia, as well as potential markets in Europe and Asia. The company collaborates with research institutions and healthcare organizations to facilitate the development and clinical evaluation of its drug delivery systems. While specific pricing structures are not disclosed, the revenue model is expected to include agreements for potential future commercialization of its flagship products, such as the Enolen® system for localized drug delivery in prostate cancer treatment.In December 2024, Alessa Therapeutics, Inc. Alessa Therapeutics is focusing on expanding its product offerings and plans to launch new products aimed at improving localized drug delivery systems for prostate cancer treatment. Additionally, the company is targeting expansion into European and Asian markets, with specific strategies being developed for these regions in the near future.

1. Seed

   Dec 12, 2024

   Amount

   $15M

   Investors

   Locked